# Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

> **NCT06632951** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 150 (estimated)

## Conditions studied

- Urothelial Carcinoma

## Interventions

- **DRUG:** Livmoniplimab
- **DRUG:** Budigalimab
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Docetaxel
- **DRUG:** Paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06632951
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2027-03
- **Final completion:** 2028-08
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06632951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06632951, "Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06632951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*